| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 173.00 | 160.00 |
| Pretax Income | -127.00 | -179.00 |
| Net Income | -118.00 | -180.00 |
| Diluted EPS | -1.16 | -1.81 |
- Net Income YoY
- +34.4%
Key highlights
- Quarterly revenue grew to $173.00 million from $160.00 million in the prior year
- Net loss narrowed by 34.4% year-over-year to $118.00 million
- Diluted earnings per share improved to -$1.16 compared to -$1.81 in Q3 2025
- Management reaffirmed full-year 2026 revenue guidance of $730 million to $760 million
- Sale of the FAYUVI Priority Review Voucher for $203 million is expected to close in November 2026
How the Period Went
Ultragenyx Pharmaceutical reported an 8.1% year-over-year increase in revenue for the third quarter of 2026, reaching $173.00 million compared to $160.00 million in the same period last year. This top-line growth was accompanied by a significant improvement in the bottom line, as the company narrowed its net loss to $118.00 million from $180.00 million in the prior-year quarter. This 34.4% year-over-year reduction in net loss was reflected in the diluted earnings per share, which improved to -$1.16 from -$1.81. The results indicate a steady expansion of the commercial product portfolio alongside a focus on reducing the quarterly burn rate.
Margins and Profitability
- Pretax loss improved to $127.00 million, down from a $179.00 million loss in Q3 2025.
- The company maintained its commitment to managing operating expenses, specifically targeting R&D and SG&A reductions for 2027.
- Non-operating items and tax benefits contributed to a narrower net loss relative to the pretax loss during the period.
- The company's liquidity position is expected to be bolstered by the $203 million sale of the FAYUVI Priority Review Voucher scheduled for late 2026.
Business Overview
Ultragenyx Pharmaceutical is a biopharmaceutical firm focused on the identification, acquisition, and development of novel therapies for rare and ultra-rare genetic diseases. The company operates within the biotechnology sector, serving niche patient populations with high unmet medical needs. Its commercialized portfolio includes treatments for metabolic and bone disorders, such as Crysvita and Dojolvi. By focusing on rare conditions, the company navigates a specialized regulatory landscape and serves end markets characterized by high barriers to entry and limited competition, while its clinical pipeline continues to explore gene therapies and enzyme replacement treatments for complex genetic conditions.
Financial Context
- The quarterly revenue of $173.00 million represents a sequential decline from the $214.0 million reported in the second quarter of 2026.
- Management reaffirmed its full-year 2026 revenue target of $730 million to $760 million, implying a strong anticipated performance in the final quarter.
- The stock currently carries a Relative Strength Index (RSI) of 54.0, suggesting a neutral market position following a 33.24% decline over the previous quarter.
- Data from the Phase 3 Enh3ance study for DTX301 in OTC deficiency is expected in the first half of 2027, representing a major upcoming clinical milestone.
Down 4.4% since our story on 4 Nov: $16.63 when we broke it → $15.90 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $15.07 |
|---|---|
| 20 Oct | $16.02 |
| 21 Oct | $15.92 |
| 22 Oct | $15.95 |
| 23 Oct | $15.65 |
| 26 Oct | $16.08 |
| 27 Oct | $16.75 |
| 28 Oct | $17.20 |
| 29 Oct | $16.78 |
| 30 Oct | $16.10 |
| 2 Nov | $16.30 |
| 3 Nov | $16.63 |
| 4 Nov | $17.16 |
| 5 Nov | $15.57 |
| 6 Nov | $15.43 |
| 9 Nov | $16.41 |
| 10 Nov | $16.14 |
| 11 Nov | $16.70 |
| 12 Nov | $16.27 |
| 13 Nov | $16.08 |
| 16 Nov | $15.90 |
| Date | Announcement | Amount |
|---|---|---|
| 03 Nov 2026 | Q3 2026 total revenueSource: ir.ultragenyx.com | $173.0 Million |
| 04 Aug 2026 | Q2 2026 total revenueSource: ir.ultragenyx.com | $214.0 Million |
| 05 May 2026 | Q1 2026 total revenueSource: SEC filing | $136.0 Million |
| 12 Feb 2026 | Q4 2025 total revenueSource: ir.ultragenyx.com | $207.0 Million |
| 04 Nov 2025 | Q3 2025 total revenueSource: ir.ultragenyx.com | $160.0 Million |
| 05 Aug 2025 | Q2 2025 total revenueSource: ir.ultragenyx.com | $166.0 Million |
| Share price | $16.63 |
|---|---|
| Market cap | $1.7B |
| Revenue (annual) | $673M |
| 1-month price change | +9.26% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Ultragenyx Pharmaceutical Inc. announcing its third quarter 2026 financial results.
Track Ultragenyx Pharmaceutical Inc. live
Get the next Ultragenyx Pharmaceutical Inc. SEC filing seconds after it lands.





